How were Bionomics' earnings last quarter?

Bionomics Limited (ASX:BNO) announced its earnings results on Friday, February, 15th. The company reported ($0.02) EPS for the quarter.

What other stocks do shareholders of Bionomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bionomics investors own include ACADIA Pharmaceuticals (ACAD) , Adverum Biotechnologies (ADVM) , Aimmune Therapeutics (AIMT) , ANI Pharmaceuticals (ANIP) , AxoGen (AXGN) , Biohaven (BHVN) , bluebird bio (BLUE) , Blueprint Medicines (BPMC) , Calithera Biosciences (CALA) and Codexis (CDXS) .

ASX:BNO

Bionomics (BNO) Stock Price, News & Analysis

→ You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad)

Free BNO Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 386,458 shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Bionomics alerts:

Ad InvestorPlace

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Bionomics

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Ad InvestorPlace

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

BNO Stock News Headlines

December 18, 2023 | investing.com

Bionomics ADR (BNOX) Earnings Dates & Reports

July 3, 2023 | finance.yahoo.com

Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 9, 2023 | finanznachrichten.de

Bionomics Ltd: Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)

February 24, 2023 | finance.yahoo.com

Bionomics First Half 2023 Earnings: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)

February 23, 2023 | finanznachrichten.de

Bionomics Ltd: Bionomics' Half-Year Report

February 5, 2023 | finance.yahoo.com

Will Bionomics (ASX:BNO) Spend Its Cash Wisely?

December 27, 2022 | finance.yahoo.com

All Focus Shifts To Bionomics' PTSD Study After Anxiety Trial Disappoints

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

December 18, 2022 | finance.yahoo.com

Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder

November 16, 2022 | finance.yahoo.com

Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States

October 25, 2022 | finance.yahoo.com

Quarterly Activities Report for September 2022

October 18, 2022 | finance.yahoo.com

Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million

October 7, 2022 | finance.yahoo.com

Bionomics (ASX:BNO) adds AU$20m to market cap in the past 7 days, though investors from five years ago are still down 84%

October 4, 2022 | finance.yahoo.com

Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference

September 24, 2022 | reuters.com

BNO.AX - Bionomics Ltd | Stock Price & Latest News | Reuters

August 30, 2022 | finance.yahoo.com

Does Bionomics Limited Unsponsored ADR (BNOX) Have the Potential to Rally 329% as Wall Street Analysts Expect?

August 27, 2022 | finance.yahoo.com

We're Keeping An Eye On Bionomics' (ASX:BNO) Cash Burn Rate

July 8, 2022 | finance.yahoo.com

Bionomics to Participate in William Blair’s Biotech Focus Conference 2022

June 13, 2022 | fool.com.au

Here’s why these 4 ASX shares are soaring today

June 13, 2022 | fool.com.au

Why these 4 ASX shares have sunk lower today

June 13, 2022 | finance.yahoo.com

Bionomics Investor Webinar

June 10, 2022 | finance.yahoo.com

Bionomics Limited (BNO.AX)

May 16, 2022 | finance.yahoo.com

Bionomics Limited to Participate in Upcoming Investor Conferences

May 11, 2022 | finance.yahoo.com

Novamind to Host Bionomics’ PREVAIL Trial for Acute Treatment of Social Anxiety Disorder

February 23, 2022 | finance.yahoo.com

Bionomics' Half-Year Report

January 14, 2022 | benzinga.com

Bionomics Limited (Nasdaq: BNOX, ASX: BNO) to...

See More Headlines

Receive BNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/15/2019
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: ASX:BNO
CUSIP: N/A
CIK: N/A
Web: www.bionomics.com.au
Phone: +61-8-83546100
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): A($0.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-24,910,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -46.14%
Return on Assets: -20.98%

Debt

Debt-to-Equity Ratio: 1.29
Current Ratio: 9.05
Quick Ratio: 12.02

Sales & Book Value

Annual Sales: $6.02 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 2.69
Book Value: A$0.03 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 1,470,000,000
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 2.13

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Adrian Hinton BEC (Age 70)
F.C.A., Financial Controller
Comp: $323.78k
Dr. Spyridon Papapetropoulos M.D. (Age 50)
Ph.D., CEO, Pres & Director
Mr. Timothy M. Cunningham CPA (Age 60)
CPA, M.B.A., Chief Financial Officer
Prof. Paul Rolan D.C.P.S.A.
F.F.P.M., F.R.A.C.P., M.B.B.S., M.D., Consultant Chief Medical Officer of Clinical Neuroscience
Dr. Julie Kerner Ph.D.
Sr. VP of Bus. Operations
Dr. Atul R. Mahableshwarkar DFAPA
M.D., Acting Chief Medical Officer
Ms. Suzanne Irwin B.Com.
FCIS, Company Sec.

Key Competitors

View All Competitors

BNO Stock Analysis - Frequently Asked Questions

How were Bionomics' earnings last quarter?: Bionomics Limited (ASX:BNO) announced its earnings results on Friday, February, 15th. The company reported ($0.02) EPS for the quarter.
What other stocks do shareholders of Bionomics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bionomics investors own include ACADIA Pharmaceuticals (ACAD), Adverum Biotechnologies (ADVM), Aimmune Therapeutics (AIMT), ANI Pharmaceuticals (ANIP), AxoGen (AXGN), Biohaven (BHVN), bluebird bio (BLUE), Blueprint Medicines (BPMC), Calithera Biosciences (CALA) and Codexis (CDXS).

This page (ASX:BNO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Bionomics (BNO) Stock Price, News & Analysis

About Bionomics

BNO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

BNO Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info